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ORIGINAL ARTICLE
Large normal-range TBP and ATXN7 CAG repeat lengths
are associated with increased lifetime risk of depression
SL Gardiner1,2, MJ van Belzen3, MW Boogaard1,3, WMC van Roon-Mom2, MP Rozing4, AM van Hemert5, JH Smit6, ATF Beekman6,
G van Grootheest6, RA Schoevers7, RC Oude Voshaar7, HC Comijs6, BWJH Penninx6, RC van der Mast5,8, RAC Roos1 and NA Aziz1
Depression is one of the most prevalent and debilitating psychiatric disorders worldwide. Recently, we showed that both relatively
short and relatively long cytosine–adenine–guanine (CAG) repeats in the huntingtin gene (HTT) are associated with an increased
risk of lifetime depression. However, to what extent the variations in CAG repeat length in the other eight polyglutamine disease-
associated genes (PDAGs) are associated with depression is still unknown. We determined the CAG repeat sizes of ATXN1, ATXN2,
ATXN3, CACNA1A, ATXN7, TBP, ATN1 and AR in two well-characterized Dutch cohorts—the Netherlands Study of Depression and
Anxiety and the Netherlands Study of Depression in Older Persons—including 2165 depressed and 1058 non-depressed individuals
—aged 18–93 years. The association between PDAG CAG repeat size and the risk for depression was assessed via binary logistic
regression. We found that the odds ratio (OR) for lifetime depression was signiﬁcantly higher for individuals with 410, compared
with subjects with ≤ 10, CAG repeats in both ATXN7 alleles (OR = 1.90, conﬁdence interval (CI) 1.26–2.85). For TBP we found a similar
association: A CAG repeat length exceeding the median in both alleles was associated with an increased risk for lifetime depression
(OR= 1.33, CI 1.00–1.76). In conclusion, we observed that carriers of either ATXN7 or TBP alleles with relatively large CAG repeat sizes
in both alleles had a substantially increased risk of lifetime depression. Our ﬁndings provide critical evidence for the notion that
repeat polymorphisms can act as complex genetic modiﬁers of depression.
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INTRODUCTION
Depression is one of the most common psychiatric disorders with
an estimated lifetime prevalence of 14.6% in high-income and
11.1% in low-income countries.1 Worldwide, depression is
responsible for 74.5 million disability-adjusted life years2 and in
2010 the total economic burden of depression in the United States
alone was estimated at $210.5 billion,3 indicating that depression
is a major strain on society. In order to create new and more
effective therapeutic and preventive strategies, unravelling the
pathogenesis of depression is imperative and elucidation of its
genetic determinants is a critical step in this process.
The heritability of major depressive disorder (MDD) has been
estimated to be between 30 and 50%.4 Nevertheless, genome-
wide association studies (GWASs) have shown limited success in
identifying its genetic basis. In a mega-analysis with more than
18 000 subjects from European ancestry, no single-nucleotide
polymorphism (SNP) reached genome-wide signiﬁcance.4 How-
ever, recently, a meta-analysis of results from three studies,
together containing 180 866 individuals, found two lead SNPs
associated with depression.5 In addition, another study combining
three cohorts in a joint analysis with a total of 478 240 subjects
found 17 independent SNPs signiﬁcantly associated with a
diagnosis of MDD,6 suggesting that GWASs can successfully
identify genetic associations with highly polygenic phenotypes.
However, the identiﬁed effect sizes were small. Moreover, to gain
sufﬁcient statistical power the sample sizes required were
extremely large and, as a consequence, unavoidably heteroge-
neous. Therefore, although GWASs have contributed greatly to
genetic mapping of complex human traits, their success has been
limited by the fact that, aside from SNPs, these studies are
unsuitable to assess the contribution of other genetic polymorph-
isms, especially DNA repeat sequences.7
Tandem repeats constitute ~ 3% of the human genome, a
higher percentage than the entirety of the protein-coding
sequences,8 substantially contributing to genetic variation.9,10
Many rare hereditary disorders are caused by expansions of simple
DNA repeat sequences.11 However, the association of DNA repeat
sequences with more common diseases is largely unknown.
Polyglutamine diseases are the most prevalent disorders caused
by an expanded DNA repeat sequence.11,12 These diseases are
caused by an expansion of a trinucleotide repeat (cytosine–
adenine–guanine (CAG)) in the translated region of various genes.
As CAG encodes the amino acid glutamine, the expansion in the
trinucleotide repeat sequence results in an elongated polygluta-
mine domain in the associated proteins.12 The most common
polyglutamine disease is Huntington disease, a severe neuro-
degenerative disorder characterized by both motor and neuro-
psychiatric impairment. Huntington disease is caused by a CAG
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repeat expansion in exon 1 of the huntingtin (HTT) gene.13,14
Recently, we demonstrated that both relatively short and relatively
large CAG repeats in the longer HTT allele are associated with
lifetime depression, suggesting that repeat polymorphisms could
also act as complex genetic modiﬁers of depression and account
for part of its ‘missing heritability’.15
Apart from Huntington disease, eight other polyglutamine
disorders, all of which are neurodegenerative disorders, are
frequently associated with considerable neuropsychiatric impair-
ment (Table 1).16–35 These rare disorders result from relatively
large repeat expansions in polyglutamine disease-associated
genes (PDAGs). However, to what extent more common repeat
length variations in the normal range of these genes could act as
genetic modiﬁers of depression in the general population is still
unknown. Hence, here we aimed to assess the contribution of CAG
repeat length variations in these other PDAGs to depression
susceptibility using data from two well-deﬁned Dutch cohorts: The
Netherlands Study of Depression and Anxiety (NESDA) and the
Netherlands Study of Depression in Old Persons (NESDO).
MATERIALS AND METHODS
We genotyped eight PDAGs (ATXN1, ATXN2, ATXN3, CACNA1A, ATXN7, TBP,
ATN1 and AR) in all participants with sufﬁcient amounts of DNA available
from blood samples of two well-characterized Dutch cohorts: the NESDA
(cohort 1) and the NESDO (cohort 2) cohorts (Table 1 and Supplementary
Figures 1–17).
Cohort 1
The NESDA is a cohort study among 2981 participants aged 18–65 years.36
The participants were recruited from the general population, general
practices and mental health-care institutes. The sample included 1973
subjects with a lifetime diagnosis of depression and/or dysthymia
(including 1925 patients with MDD), 635 subjects with a lifetime anxiety
disorder without lifetime depression and 373 healthy controls.36 Diagnoses
were made in accordance with the Diagnostic and Statistical Manuel of
Mental Disorders Fourth Edition criteria using the WHO Composite
International Diagnostic Interview.37
Cohort 2
The NESDO is a cohort study among 510 participants aged 60–93 years.38
The participants were recruited from both general practices and mental
health-care institutes. The sample included 378 depressed individuals (360
with MDD) and 132 healthy controls. The same methods for diagnosing
depression were used as in the NESDA.38
Genotyping
A polymerase chain reaction (PCR) was performed in a TProfessional
thermocycler (Biometra, Westburg, Leusden, the Netherlands) with labelled
primers ﬂanking the CAG stretch of the PDAGs (Biolegio, Nijmegen, the
Netherlands; Supplementary Table 1). The PCR was performed using 10 ng
of genomic DNA, 1 × OneTaq mastermix (New England Biolabs, Ipswich,
MA, USA, OneTaq Hot start with GC Buffer mastermix), 1 μl of primer Mix A
or B (Supplementary Table 1) and Aqua B. Braun water to a ﬁnal volume of
10 μl. The PCR was run with 27 cycles of 30 s, denaturation at 94 °C, 1 min
of annealing at 60 °C and 2 min elongation at 68 °C, preceded by 5 min of
initial denaturation at 94 °C. Final elongation was performed at 69 °C for
5 min. Every PCR included a negative control without genomic DNA and a
reference sample of CEPH 1347-02 genomic DNA. The PCR products were
run on an ABI 3730 automatic DNA sequencer (Applied Biosystems, Foster
City, CA, USA) and analysed using the GeneMarker software version 2.4.0.
(SoftGenetics, State College, PA, USA). For every analysis, we included three
controls with known CAG repeat lengths for each PDAG to assure that
every run was performed reliably. All assessments were made with cases
and controls randomized on plates and blinding with respect to disease
status information.
Statistical analysis
Binary logistic regression was used to assess whether CAG repeat sizes in
the two alleles of each PDAG were associated with the risk of lifetime
depression. For each PDAG, in an initial model, the presence of lifetime
depression (that is, MDD and/or dysthymia) was set as the dependent
variable and the CAG repeat lengths of both alleles were used as the
independent variables. To assess interaction effects between the two
alleles or nonlinear effects, a product term of the two alleles and a
quadratic term for each allele were added to the model. In case the
product term or the quadratic terms were not signiﬁcant, these predictors
were removed from the model and the analysis was repeated.
Subsequently, we adjusted the results for the effects of sex, age and
education level (coded as ‘basic’, ‘intermediate’ and ‘high’36,38) in order to
assess whether the effect of CAG repeat size variations was independent of
these well-established risk factors for depression. The Nagelkerke R2 was
used to assess the proportion of variability explained by the predictors in
the model. To account for potential effects of heteroscedasticity and
inﬂuential points, all statistical signiﬁcance tests were based on robust
estimators of s.e.'s. Moreover, to visualise our results as well as to assure
Table 1. Summary genotyped polyglutamine disease-associated genes
Gene Disease Protein CAG repeat ranges Allele Mean Median N Range No. of intermediatea No. of pathologicala
Normal Pathological
ATXN1 SCA1 Ataxin-1 6–39 41–83 Short 29.22 29.00 3228 18–35 0 0
Long 30.76 30.00 3228 26–39 0 0
ATXN2 SCA2 Ataxin-2 14–32 33–500 Short 21.91 22.00 3236 14–24 0 0
Long 22.35 22.00 3236 22–36 0 2 (33, 36)
ATXN3 SCA3 Ataxin-3 12–44 52–87 Short 18.96 20.00 3235 13–33 0 0
Long 24.27 23.00 3235 13–49 1 (49) 0
CACNA1A SCA6 CACNA1A 4–18 20–33 Short 10.52 11.00 3220 4–14 0 0
Long 12.45 13.00 3220 4–22 0 1 (22)
ATXN7 SCA7 Ataxin-7 3–19 37–460 Short 10.04 10.00 2979 7–15 0 0
Long 10.85 10.00 2979 7–19 0 0
TBP SCA17 TBP 25–43 45–66 Short 36.31 37.00 3238 27–39 0 0
Long 37.89 38.00 3238 32–48 1 (44) 1 (48)
ATN1 DRPLA Atrophin-1 3–38 48–93 Short 12.36 14.00 3228 5–22 0 0
Long 15.47 15.00 3228 8–30 0 0
AR SMBA Androgen receptor 6–36 38–72 Short 20.80 21.00 3228 8–36 0 0
Long 22.90 23.00 3228 8–36 0 0
Abbreviations: CACNA1A, calcium channel, voltage-dependent P/Q type, α 1A subunit; CAG, cytosine–adenine–guanine; DRPLA, dentatorubropallidoluysian
atrophy; SBMA, spinal bulbar muscular atrophy; SCA, spinocerebellar ataxia; TBP, thymine-adenine-thymine-adenine (TATA) box-binding protein.
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that the results were not unduly affected by violated model assumptions,
we also applied a non-parametric method: we calculated the odds ratios
(ORs) for a lifetime diagnosis of depression per CAG repeat group. The CAG
repeat groups were deﬁned based on the median CAG repeat size of each
allele. A division as such resulted in three adequately sized groups: I, both
alleles⩽ their median; II, the relatively shorter allele⩽ the median and the
relatively longer allele4the median; III, both alleles4their median.
Subsequently, the ORs were compared with the Fisher’s exact test. In
order to account for multiple testing, we applied a false discovery rate
correction as described by Benjamini and Hochberg, assuming eight
independent tests with a two-sided α of 0.05.39 All data are displayed as
means and 95% conﬁdence intervals (CIs), unless otherwise speciﬁed. All
analyses were performed in SPSS version 23.0 (IBM SPSS Statistics for
Windows, IBM, Armonk, NY, USA).
RESULTS
Risk of lifetime depression increases with higher ATXN7 CAG
repeat sizes
In total, we were able to genotype a total of 2979 participants for
ATXN7 (Table 1). This included 1998 depressed subjects and 981
non-depressed subjects. For 512 individuals, too little DNA
material was available to determine the CAG repeat length in
ATXN7 (Supplementary Table 2). These lacking samples were
missing completely at random. The CAG repeat lengths ranged
from 7 to 19 repeats (Table 1).
We found a signiﬁcant association between the risk of lifetime
depression and the CAG repeat length of ATXN7 in the shorter
allele (β= 0.202, P= 0.006). Adjusting for the effects of gender, age
and education hardly changed these results (β= 0.184, P= 0.013;
Supplementary Table 3). After adjusting for multiple testing, this
association remained signiﬁcant. Inclusion of the CAG repeat
length of the ATXN7 allele in the model increased the proportion
of explained genetic variation from the baseline model including
only gender, age and level of education by 0.004 (that is, the R2
increased from 0.024 to 0.028). Considering our control group
included subjects with anxiety disorders without comorbid
depression (n= 348), we also performed a sensitivity analysis by
excluding these individuals from the control group. Neither the
parameter estimates nor their signiﬁcance were materially altered
by this procedure (β= 0.215, P= 0.009).
For the non-parametric method, we divided all subjects based
on the median CAG repeat size for each ATXN7 allele (median
relatively short allele = 10, median relatively long allele = 10) and
compared the ORs of lifetime depression among the groups
(Table 2). The group containing the largest number of individuals
was used as the reference category. Comparing the other groups
to the reference category demonstrated the signiﬁcant effect of
the shorter allele on the risk of lifetime depression (Figure 1).
When the relatively short allele and thus also the relatively long
allele both contained a CAG repeat length larger than 10 repeats,
the odds for lifetime depression almost doubled compared with
the reference category in which both ATXN7 alleles had a CAG
repeat number equal to or smaller than the median.
TBP CAG repeat sizes in both alleles interact to affect the risk of
lifetime depression
A total of 3238 individuals were genotyped for TBP (Table 1). This
included 2180 people diagnosed with lifetime depression and
1058 non-depressed people. For 253 individuals, too little DNA
material was available to determine the CAG repeat length in TBP
(Supplementary Table 2). The lacking samples were missing
completely at random. For TBP, we found CAG repeat lengths
ranging between 27 and 48 repeats (Table 1).
We found the interaction between the number of CAG repeats
in the two TBP alleles to be signiﬁcantly associated with the risk of
lifetime depression (TBP short allele: β=− 2.270, P= 0.004; TBP
long allele: β=− 2.112, P= 0.006; TBP interaction term: β= 0.060,
P= 0.005). When adjusting for the effects of gender, age and
Table 2. The distribution of participants in three ATXN7 categories
ATXN7 category Allele Mean Range Lifetime depressiona No lifetime depressionb Odds ratio (95% CI)
Ic Short 9.94 7–10 1220 619 1.00
Long 10.00 7–10
II Short 9.97 7–10 662 331 1.01 (0.86–1.20)
Long 12.18 11–19
III Short 11.90 11–15 116 31 (1.26–2.85)d
Long 12.54 11–18
Abbreviations: I, both alleles of ATXN7 contain a CAG repeat number ⩽ 10; II, the relatively longer ATXN7 allele contains a CAG repeat number 410 and the
relatively shorter allele contains a CAG repeat number ⩽ 10; III, both alleles of ATXN7 contain a CAG repeat number410; CAG, cytosine–adenine–guanine; CI,
conﬁdence interval. aFigures represent the number of subjects per ATXN7 category in the group with lifetime depression. bFigures represent the number of
subjects per ATXN7 category in the group with no lifetime depression. cThis category contains the largest number of subjects and was therefore chosen as the
reference category for odds ratio calculation. dPo0.01 by Fisher’s exact test in comparison with the reference category.
Figure 1. Odds ratio for lifetime depression per ATXN7 category. The
odds ratio for lifetime depression increases signiﬁcantly when both
the relatively long ATXN7 allele and the relatively short ATXN7 allele
exceed the median CAG repeat number of 10. The odds of having
lifetime depression almost doubles. The group having both alleles
with a CAG repeat number ⩽ 10 was the largest and, therefore, was
set as the reference category. I, both alleles of ATXN7 contain a CAG
repeat number ⩽ 10; II, the relatively longer ATXN7 allele contains a
CAG repeat number410 and the relatively shorter allele contains a
CAG repeat number ⩽ 10; III, both alleles of ATXN7 contain a CAG
repeat number 410. Error bars indicate± s.e. **Po0.01 by the
Fisher’s exact test in comparison with the reference category; CAG,
cytosine–adenine–guanine.
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education, the results hardly changed (TBP short allele: β=− 2.302,
P= 0.004; TBP long allele: β=− 2.150, P= 0.005; TBP interaction
term: β= 0.061, P= 0.005; Supplementary Table 3). Furthermore,
the results remained signiﬁcant after performing the sensitivity
analysis and applying the false discovery rate correction.39 The
proportion of explained genetic variation increased by 0.005 from
the baseline model including only gender, age and level of
education (that is, the R2 increased from 0.023 to 0.028).
For the non-parametric method, we divided all subjects in three
groups based on the median CAG repeat size for each TBP allele
(median relatively short TBP allele = 37, median relatively long TBP
allele = 38) and compared the ORs of lifetime depression among
the groups (Table 3). The largest group was set as the reference
category. The comparison of the groups demonstrated the
signiﬁcant effect of the interaction between the relatively short
TBP allele and the relatively long TBP allele on the risk of
depression. The risk of lifetime depression was signiﬁcantly higher
when both TBP alleles had a CAG repeat length exceeding their
median compared with the reference category, in which both
alleles had a CAG repeat number equal to or lower than their
median (Figure 2).
CAG repeat sizes in other PDAGs were not associated with risk of
lifetime depression
The number of CAG repeats in ATXN1, ATXN2, ATXN3, CACNA1A,
ATN1 and AR were not associated with the risk of lifetime
depression. Neither the main effect of the alleles, nor the
interactions between the two alleles, or the quadratic terms, were
signiﬁcantly associated with the presence of lifetime depression in
the combined cohort. As AR is located on the X-chromosome, we
performed one analysis stratifying the data by gender and another
analysis using only either the relatively short or the relatively long
allele in the model. None of the two approaches demonstrated a
signiﬁcant association between CAG repeat number in AR and
depression (Supplementary Table 3).
The effects of HTT, ATXN7 and TBP CAG repeat sizes are
independent
In previous research, we demonstrated that both the main term of
the longer HTT allele and the quadratic term of the longer HTT
allele are also signiﬁcantly associated with a diagnosis of lifetime
depression.15 To assess the contribution of the CAG repeat
polymorphisms in all PDAGs to depression risk, we examined the
degree to which HTT, ATXN7 and TBP CAG repeat sizes explain
depression heritability. To this end, we applied a multivariate
model with the CAG repeat sizes in these three PDAGs as
predictors. In addition, we adjusted for the effects of gender, age
and education. We found that the parameter estimates as well as
their associated statistical signiﬁcances hardly changed, indicating
that the effects of HTT, ATXN7 and TBP CAG repeat sizes on
depression susceptibility are mutually independent (HTT long
allele: β=− 0.286, P= 0.018; HTT long allele quadratic term
β= 0.006, P= 0.017; ATXN7 short allele: β= 0.210, P= 0.005; TBP
short allele: β=− 2.728, P= 0.001; TBP long allele, β=− 2.566;
P= 0.001; TBP interaction term: β= 0.072, P= 0.001). Inclusion of
the CAG repeat sizes in HTT, ATXN7 and TBP in the model
increased R2 by 0.014 from the baseline model including only
gender, age and level of education (from 0.024 to 0.038),
indicating that the CAG repeat lengths in these PDAGs can
account for an additional 1.4% of the genetic variation on the
observed probability scale. We also derived the R2 on the liability
scale as described previously.40 Assuming that depression has a
lifetime prevalence of ~ 15% in the Netherlands41 and adjusting
for the oversampling of patients with depression in our cohort, the
R2 on the liability scale was 0.0191, indicating that CAG repeat size
polymorphisms in HTT, ATXN7 and TBP together can account for
~ 1.9% of depression heritability.
Table 3. The distribution of participants in three TBP categories
TBP category Allele Mean Range Lifetime depressiona No lifetime depressionb Odds ratio (95% CI)
Ic Short 35.78 27–37 1462 716 1.00
Long 37.47 32–38
II Short 36.04 30–37 230 93 1.21 (0.94–1.57)
Long 39.30 39–48
III Short 38.09 38–39 201 74 1.33 (1.00–1.76)d
Long 39.28 39–44
I, both TBP alleles contain a CAG repeat number⩽ their median; II, the relatively longer TBP allele contains a CAG repeat number4the median and the
relatively shorter TBP allele contains a CAG repeat number⩽ the median; III, both TBP alleles contain a CAG repeat number4their median (median short
allele= 37, median long allele= 38); CAG, cytosine–adenine–guanine; CI, conﬁdence interval. aFigures represent the number of subjects per TBP category in
the group with lifetime depression. bFigures represent the number of subjects per TBP category in the group with no lifetime depression. cThis category
contains the largest number of subjects and was therefore chosen as the reference category for odds ratio calculation. dPo0.05 by Fisher’s exact test in
comparison with the reference category.
Figure 2. Odds ratio for lifetime depression per TBP category. The
odds ratio for lifetime depression increases signiﬁcantly when both
the relatively shorter TBP allele and the relatively longer TBP allele
exceed their median CAG repeat number (median short allele= 37,
median long allele= 38). The group with both alleles being equal to
or smaller than their medians was the largest and, therefore, is
deﬁned as the reference category. I, both TBP alleles contain a CAG
repeat number ⩽ their median; II, the relatively longer TBP allele
contains a CAG repeat number4the median and the relatively
shorter TBP allele contains a CAG repeat number ⩽ the median; III,
both TBP alleles contain a CAG repeat number4 their median. Error
bars indicate±one s.e. *Po0.05 by the Fisher’s exact test in
comparison with the reference category. CAG, cytosine–adenine–
guanine; TBP, thymine-adenine-thymine-adenine (TATA) box-binding
protein.
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The prevalence of intermediate and pathological PGDA alleles
In total, four genotyped subjects had a CAG repeat number in the
pathological range of a PDAG. One individual had a CAG repeat
number of 22 in CACNA1A, one subject had a CAG repeat number
of 48 in TBP and two people had a CAG repeat number of 33 and
36 in ATXN2 (Table 1). All four were depressed, but at the ages of
53 years for CACNA1A, 59 years for TBP, and 26 and 31 years for
ATXN2, none had been diagnosed with the respective diseases
(that is, SCA6, SCA17 and SCA2).
One person had a CAG repeat number in the longer TBP allele of
44, belonging to the intermediate range. This individual was also
diagnosed with lifetime depression. Furthermore, one depressed
individual had an intermediate CAG repeat number in the longer
allele of ATXN3 (that is, 49 repeats). For ATXN1, ATXN7, ATN1 and
AR all subjects had a CAG repeat number within the normal range
(Table 1).
When we included the two depressed individuals with a CAG
repeat length in the reduced penetrance range of HTT found
previously,15 we observed a trend for a higher proportion of
subjects with a CAG repeat in the intermediate or pathological
range of a PDAG in the depressed group (P= 0.059).
DISCUSSION
To our knowledge, this is the ﬁrst study assessing the inﬂuence of
CAG repeat size variations in the normal range of PDAGs—other
than HTT—on the risk of lifetime depression. Interestingly, we
found an association between the presence of lifetime depression
and the CAG repeat length in two PDAGs, that is, ATXN7 and TBP.
The main relationship we found was that when the CAG repeat
number of both alleles in either ATXN7 or TBP was relatively large,
the odds for a diagnosis of lifetime depression markedly
increased. Moreover, six genotyped individuals had a CAG repeat
number in at least one of their PDAGs that extended into the
intermediate or pathological range (two intermediate, four
pathological). All of these subjects were diagnosed with lifetime
depression. These ﬁndings are in support of the hypothesis that
repeat polymorphisms may act as complex genetic modiﬁers of
depression and thus could account for part of its ‘missing
heritability’.
In our study, we found that the odds of lifetime depression
almost doubled in individuals with a CAG repeat length of410 in
both ATXN7 alleles. Similarly, we found that the risk of lifetime
depression markedly increased (OR = 1.33) in individuals who had
a CAG repeat length exceeding the median in both TBP alleles.
These effect sizes are considerable, especially when compared
with the effect sizes of the two most signiﬁcant SNPs found in a
recent GWAS: OR= 0.955 (95% CI 0.943–0.968) and OR= 1.051
(95% CI 1.036–1.067).6 Although we cannot fully exclude potential
modifying effects of SNPs in linkage disequilibrium (LD) with
ATXN7 and TBP, the fact that such SNPs in these PDAGs have not
been detected before in GWASs suggests that the inﬂuence of
other genetic variants in LD with the CAG repeat size in these
genes is likely to be minimal.42 Furthermore, we found that CAG
repeat size polymorphisms in HTT, ATXN7 and TBP together can
account for ~ 1.9% of depression heritability. Using the same
population prevalence of 15% for depression, the meta-analysis in
the recent GWAS calculated a heritability of 5.9%.6 The amount of
variance explained by these SNPs is larger than the amount
explained by the CAG repeat polymorphisms we found. However,
the meta-analysis in this GWAS examined SNPs in the entire
genome of 326 113 individuals,6 whereas our estimation was
based on the effects of CAG repeat variations in only nine PDAGs.
This fact suggests that investigating additional repeat polymorph-
isms in the human genome could lead to the identiﬁcation of
many more novel genetic determinants of depression. The
importance of investigating repeat polymorphisms in association
with health and disease has been described in previous literature
and begins to gain more recognition within the ﬁeld of genetic
research.9,10,43–46
CAG repeat numbers exceeding 36 in ATXN7 are responsible for
the severe neurodegenerative disorder spinocerebellar ataxia type
7 (SCA7).34 SCA7 is a progressive autosomal-dominant neurode-
generative disorder primarily characterized by cerebellar ataxia
and macular degeneration.47 Although depressive symptoms are a
frequent ﬁnding in many neurodegenerative disorders, the
prevalence of depression has hardly been assessed in SCA7.48–51
Our ﬁndings suggest that depression might be an underappre-
ciated feature of SCA7, which needs further characterisation. A
CAG repeat number in TBP larger than 48 causes the severe
progressive neurodegenerative disorder SCA17.34 Aside from
cerebellar ataxia, dementia and pyramidal symptoms, in 67% of
the cases SCA17 is also accompanied by psychiatric signs and
symptoms, including depression, behavioural changes as well as
psychosis.52 Initial symptoms of SCA17 have been described to
include depression.53
The gene ATXN7 encodes the protein ataxin-7. Apart from
several important cellular functions,51 ataxin-7 is an integral part
of the TATA-binding protein-free TAF-containing complex.54 TATA-
binding protein-free TAF-containing complex allows for the
initiation of transcription via RNA polymerase II in the absence
of the RNA polymerase II transcription factor D.55 Interestingly, the
TATA-box-binding protein (TBP) that is encoded by TBP, is the
DNA-binding subunit of RNA polymerase II transcription factor D.
TBP anchors RNA polymerase II transcription factor D to the TATA-
box upstream of the ﬁrst codon, allowing for the initiation of
transcription via RNA polymerase II.56 Thus, TBP as well as ataxin-7
seem to have a part in the initiation of transcription via RNA
polymerase II. RNA polymerase II catalyses the transcription of
DNA to synthesise precursors of mRNA, snRNA and microRNA.57,58
Numerous studies indicate an altered mRNA expression of
proteins such as the serotonin 5-HT1A receptor,
59,60 brain-
derived neurotropic factor61–64 and corticotrophin-releasing
factor65,66 in subjects suffering from MDD compared with controls.
Furthermore, the evidence supporting a role for the dysfunction of
microRNA-mediated regulated gene expression in MDD is
increasing.67–71 Therefore, CAG repeat variations in either ATXN7
or TBP could modulate the function of RNA polymerase II, and
thereby lead to changes in mRNA and microRNA expression that
have previously been associated with MDD.59–71 Hence, we intend
to investigate the effect of CAG repeat length variations within the
normal range in ATXN7 and TBP on the expression and function of
proteins thought to be associated with depression in a
cellular model.
The presence of one subject with a CAG repeat size in the
pathological range of CACNA1A, one subject with a CAG repeat
size in the pathological range of TBP and two subjects with a
pathological CAG repeat size in ATXN2 within our two cohorts is
remarkable. For these individuals, depression is apparently the ﬁrst
symptom with which SCA6, SCA17 or SCA2 manifests itself. The
prevalence of an autosomal-dominant cerebral ataxia among
Europeans is estimated to be between 1 and 3 per 100 000, of
which 2% are diagnosed with SCA6, o1% with SCA17 and 10%
with SCA2,72 resulting in a prevalence of 0.02–0.06 per 100 000,
o0.01–0.03 per 10 000 and 0.10–0.30 per 100 000 for SCA6,
SCA17 and SCA2, respectively. These numbers are in stark contrast
to the substantially higher prevalence estimates in patients with
depression in our study, 90 per 100 000 for SCA6, 50 per 100 000
for SCA17 and 50 per 100 000 for SCA2. Previously, we also found
two individuals with incompletely penetrant HTT alleles (that is,
those containing 36–39 CAG repeats) in this same population,
both of whom suffered from depression.15 The difference in
proportion of individuals with intermediate or pathological CAG
repeat lengths in PDAGs indeed tended to be higher in depressed
compared with control subjects, although likely due to the relative
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rarity of these expanded alleles the results did not reach statistical
signiﬁcance. Our ﬁndings are in line with another study that
estimated the prevalence of incompletely penetrant HTT alleles in
MDD patients to be ~ 3 in 1000, whereas such alleles were absent
in the control group.73 Together, these ﬁndings suggest that
depression could be the ﬁrst manifestation of polyglutamine
diseases and that, conversely, polyglutamine diseases might be
underdiagnosed in patients with depression.
In this study, we analysed a homogenous population by using
samples from two Dutch cohorts for our analysis, thereby
minimising the impact of population stratiﬁcation. However, the
use of a uniform group of individuals could also be seen as a
limitation of our study, as it might have consequences for the
generalisability of our ﬁndings. However, our results appear robust
and consistent, although conﬁrmation of our ﬁndings in other
populations, as well as the elucidation of their pathophysiological
basis, is warranted.
In conclusion, we observed a signiﬁcant association between
the risk of lifetime depression and CAG repeat size in ATXN7 and
TBP. A relatively large CAG repeat number in both alleles of either
ATXN7 or TBP substantially increased depression risk. Our ﬁndings
add more critical evidence to the notion that repeat polymorph-
isms could act as complex genetic modiﬁers of depression and,
therefore, could partially account for its ‘missing heritability’. In
addition, our ﬁndings indicate that the role of DNA repeat
polymorphisms as potential genetic modiﬁers of other psychiatric
disorders also needs further scrutiny.
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